Chr del(5q)

News alerts, weekly reports and conference planners

Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval SOHO 2022 - 1 week (New C3) lenalidomide Sensitive : A1 SOHO 2022 - 1wk	lenalidomide Sensitive: A1 - Approval SOHO 2022 - 1 week lenalidomide Sensitive : A1 SOHO 2022 - 1 week - (New C3)
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3

Associations